In this podcast, we speak to Dr Brian Ference, a cardiologist and genetic epidemiologist from Cambridge University in the United Kingdom. Dr Ference designs Mendelian randomisation studies to help answer some of the big questions in cardiology, including: what magnitude of benefit could we achieve with earlier, sustained low levels of LDL-cholesterol on lifetime risk of CV disease, and does it actually matter how we achieve these levels?

This article was sponsored by Amgen, which has no control over editorial content. The content is entirely independent and based on published studies and experts’ opinions, the views expressed are not necessarily those of Amgen.